NURECA LIMITED is a Healthcare Equipment & Supplies company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 256 | 111 | 92 | 110 | 147 |
| EBITDA (ex other income) | 56 | (15) | (10) | (8) | 0 |
| margin % | 21.7 | (13.5) | (11.1) | (6.9) | 0.1 |
| Owners' profit | 0 | 0 | (2) | 0 | 0 |
| EPS, as reported (₹) | 44.96 | (8.25) | (1.79) | 0.85 | 2.11 |
| ROE % · ROCE % | 22.1 · 29.8 | (4.2) · (5.2) | (0.9) · (1.0) | 0.4 · 1.3 | 1.2 · 3.4 |
| Debt / equity (x) | 0.02 | 0.02 | 0.00 | 0.01 | 0.00 |
| Cash from operations | 1 | 10 | (3) | (19) | 3 |
| Capex | (3) | (0) | (1) | (4) | (7) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 31 | 26 | 32 | 34 | 72 | 40 | 35 | 40 |
| Profit before tax | (0) | (3) | 2 | 1 | 6 | 5 | (6) | 4 |
| Net profit | (0) | (3) | 2 | 1 | 4 | 4 | (6) | 3 |
| EPS (₹) | (0.48) | (2.80) | 2.47 | 0.81 | 4.44 | 3.91 | (6.45) | 3.21 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| POLY MEDICURE LIMITED | 17,626 | 55.9 | 5.60 | 32.3 | 10.2 | 12.6 | 19.0 | 30.2 |
| FISCHER MEDICAL VENTURE L | 2,353 | 15.0 | 6.11 | 43.6 | 8.1 | 11.3 | — | 15.5 |
| TARSONS PRODUCTS LIMITED | 1,657 | 149.0 | 2.61 | 14.3 | 2.3 | 2.4 | — | 29.0 |
| LAXMI DENTAL LIMITED | 1,121 | 36.0 | 4.59 | 24.1 | 11.8 | 11.0 | — | 22.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 10 Sept 2026 · Nureca: Promoter Group member buys 1,000 shares | ownership changes | medium | — | — |
| 10 Sept 2026 · Nureca promoter Saurabh Goyal hikes stake to 69.55 percent via open market buys | ownership changes | high | — | — |
| 10 Sept 2026 · Promoter Group member Smita Goyal buys 57,337 shares of Nureca | ownership changes | high | — | — |
| 9 Sept 2026 · Promoter Group member Smita Goyal purchases 1,050 Nureca shares | ownership changes | medium | — | — |
| 29 Aug 2026 · Promoter Group Director Smita Goyal buys 9,974 Nureca shares via open market | ownership changes | medium | — | — |
| 21 Aug 2026 · Nureca: GST demand for FY22 dropped after rectification, Rs 15.4 lakh ITC reversed | regulatory legal | high | — | — |
| 11 Aug 2026 · Promoter Group member Smita Goyal buys 39,345 shares in Nureca | ownership changes | medium | — | — |
| 10 Aug 2026 · Nureca shares GST order details; around Rs 15.4 lakh ITC reversal | regulatory legal | high | — | — |
| 7 Aug 2026 · Nureca resolves GST dispute for FY 2021-22, pays Rs 15.4 lakh | regulatory legal | high | — | — |
| 28 Jul 2026 · Nureca AGM 2026: All 4 resolutions passed, director reappointments approved | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| FABTECH TECHNOLOGIES LTD |
| 650 |
| 10.6 |
| 1.55 |
| 10.6 |
| 9.1 |
| 10.7 |
| — |
| 9.9 |
| Hemant Surgical Industries Lim | 613 | 23.4 | — | — | — | 16.7 | — | — |
| Prevest Denpro Limited | 489 | 16.5 | — | — | — | 21.9 | — | — |
| NURECA LIMITED ◆ | 318 | 65.2 | 1.76 | 38.3 | 1.2 | 2.7 | (7.2) | 13.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 65.2 | 20.0 | 15 of 17 | 13% |
| P/B | 1.8 | 2.7 | 4 of 11 | 70% |
| ROCE | 2.7 | 11.3 | 15 of 17 | 13% |
| ROE | 1.1 | 8.1 | 10 of 11 | 10% |
| Debt / Equity | 0.0 | 0.1 | 3 of 11 | 80% |
| EBITDA margin | 13.0 | 16.7 | 9 of 11 | 20% |
| Revenue growth | 18.0 | 13.9 | 6 of 13 | 58% |
| Profit growth | 277.4 | 75.5 | 2 of 10 | 89% |
| Market cap | 318 | 175 | 8 of 17 | 56% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
